Patents by Inventor Erik James Hicken

Erik James Hicken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190177328
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Applicants: Array BioPharma Inc., Celgene Corporation
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Publication number: 20190062330
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca
  • Patent number: 10189845
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 29, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Patent number: 10125134
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 13, 2018
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Henry J. Zecca
  • Publication number: 20180086758
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: September 27, 2017
    Publication date: March 29, 2018
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marms├Ąter, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Publication number: 20180072723
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: November 15, 2017
    Publication date: March 15, 2018
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca
  • Publication number: 20170362240
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Applicants: ARRAY BIOPHARMA INC., CELGENE CORPORATION
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Patent number: 9809590
    Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 7, 2017
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Patent number: 9670208
    Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 6, 2017
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Adam Cook, John Gaudino, Indrani W. Gunawardana, Erik James Hicken, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Jacob Schwarz, Huifen Chen, Lewis Gazzard, Jane Schmidt, Steve Do
  • Publication number: 20160304519
    Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Adam Cook, John Gaudino, Indrani W. Gunawardana, Erik James Hicken, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Jacob Schwarz, Huifen Chen, Lewis Gazzard, Jane Schmidt, Steve Do
  • Publication number: 20160002232
    Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Patent number: 9174981
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: November 3, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Patent number: 8987251
    Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 24, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Hicks, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • Patent number: 8895550
    Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: November 25, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Robert Kirk DeLisle, Julie Marie Hicks, Erik James Hicken, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, John E. Robinson, Qian Zhao
  • Publication number: 20140228349
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Application
    Filed: October 9, 2012
    Publication date: August 14, 2014
    Inventors: Mark Laurence Boys, Laurence E. Burgess, C. Todd Eary, Robert Groneberg, Bruno P. Hache, Darren Harvey, Erik James Hicken, Christopher F. Kraser, Ellen Laird, David A. Moreno, Mark C. Munson, Li Ren, John E. Robinson, Stephen T. Schlachter
  • Publication number: 20140045835
    Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 13, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Robert Kirk DeLisle, Julie Marie Hicks, Erik James Hicken, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, John E. Robinson, Qian Zhao
  • Publication number: 20140045817
    Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Hicks, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • Patent number: 8575145
    Abstract: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: November 5, 2013
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Greschuk, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • Publication number: 20130274244
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 17, 2013
    Inventors: Mark Laurence Boys, Robert Kirk Delisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Patent number: 8557809
    Abstract: Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: October 15, 2013
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Robert Kirk DeLisle, Julie Marie Greschuk, Erik James Hicken, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, John E. Robinson, Qian Zhao